These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33094598)

  • 21. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
    Sullivan RJ; Flaherty KT
    Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [An unusual digestive complication under anti-PD-1 (pembrolizumab)].
    Calvani J; Elia R; Battistella M; Delyon J; Vivier-Chicoteau J; Gornet JM; Lebbé C; Baroudjian B; Bertheau P
    Ann Pathol; 2020 Jul; 40(4):320-323. PubMed ID: 32107038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission.
    Civardi G; Medioli A; Braghieri C; Ambroggi M; Immovilli P; Orsucci S; Contini P; Aronica G; Cavanna L
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
    Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
    Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
    Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
    J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
    Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
    Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma.
    Marjanska A; Galazka P; Marjanski M; Wysocki M; Styczynski J
    Anticancer Res; 2019 Jul; 39(7):3945-3947. PubMed ID: 31262925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis.
    Johncilla M; Grover S; Zhang X; Jain D; Srivastava A
    Histopathology; 2020 Mar; 76(4):531-539. PubMed ID: 31692018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab-Induced Pancytopenia: A Case Report.
    Atwal D; Joshi KP; Ravilla R; Mahmoud F
    Perm J; 2017; 21():17-004. PubMed ID: 28746020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma.
    Khoja L; Maurice C; Chappell M; MacMillan L; Al-Habeeb AS; Al-Faraidy N; Butler MO; Rogalla P; Mason W; Joshua AM; Hogg D
    Cancer Immunol Res; 2016 Mar; 4(3):175-8. PubMed ID: 26822024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
    Abu Samra K; Valdes-Navarro M; Lee S; Swan R; Foster CS; Anesi SD
    Eur J Ophthalmol; 2016 Apr; 26(3):e46-8. PubMed ID: 26692064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unusual severe gastritis and gastric ulcers caused by pembrolizumab.
    Liu WT; Li YF; Hsieh TY
    J Postgrad Med; 2022; 68(1):38-40. PubMed ID: 34121670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
    J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma.
    Elmasry M; Dong B; Rios C; Breaux A; Miller D
    Am J Med Sci; 2022 Sep; 364(3):343-346. PubMed ID: 35276075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.